Barclays PLC Increases Stock Holdings in Liquidia Co. (NASDAQ:LQDA)

Barclays PLC increased its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 265.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 99,984 shares of the company’s stock after acquiring an additional 72,591 shares during the period. Barclays PLC’s holdings in Liquidia were worth $999,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC purchased a new position in shares of Liquidia during the 2nd quarter valued at approximately $27,000. Clear Harbor Asset Management LLC acquired a new position in Liquidia in the 3rd quarter valued at $100,000. Signaturefd LLC raised its stake in Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after purchasing an additional 9,984 shares during the last quarter. Ballentine Partners LLC acquired a new position in Liquidia in the 3rd quarter valued at $110,000. Finally, Whitcomb & Hess Inc. raised its stake in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after purchasing an additional 1,074 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Down 0.5 %

Shares of LQDA opened at $11.51 on Tuesday. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.99. The company has a market capitalization of $974.17 million, a PE ratio of -7.06 and a beta of 0.22. The stock has a fifty day simple moving average of $10.95 and a two-hundred day simple moving average of $11.05.

Analyst Upgrades and Downgrades

LQDA has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Lifesci Capital initiated coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company. Scotiabank initiated coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Wells Fargo & Company initiated coverage on Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Buy” and an average price target of $25.38.

Insider Buying and Selling

In related news, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $28,619.36. Following the transaction, the general counsel now owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This trade represents a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,007 shares of company stock valued at $245,780. 30.10% of the stock is currently owned by insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).